2024-06 Las Vegas

Section 1: Best Practices in Prescribing Opioids: A regulatory perspective .

• Describe evolving opioid prescribing and regulatory practices in the United States.

• Discuss recently released opioid prescribing guidelines, highlighting the relevance to outpatient treatment of pain.

• Describe best practices and patient care resources for managing patients with acute or chronic nonmalignant pain, highlighting guidance from a regulatory per-spective. Regulatory Cases with Opioid Medications

• Apply best practices in the prescribing of opioids and other controlled substances.

• Discuss key physiologic and common pathophysiologic changes of aging that impact drug therapy .

Session 2: Addiction as a Brain Disease:

• Examine the neurobiological responses to substances of abuse,.

• Describe howyour brain responds to drugs.

• Explore how addiction affects the brain.

• Examine behavioral changes in addiction.

Session 3: Screening, Brief Intervention, and Referral to Treatment (SBIRT):

• Explore SBIRT (Screening, Brief Intervention, and Referral to Treatment) as a routine part of care in all healthcare settings.

• Review guidelines for providing, billing, and coding for SBIRT services. Case Study in Acute Post-Operative Pain and Diversion Control :

• Integrate best practicesor appropriate prescribing of controlled substances, screening for substance use disorders, and diversion control.

Session 1:  Avoiding Drug Injury in Older Adults: A focus on controlled substances

• Discuss key physiologic and common pathophysiologic changes of aging that impact drug therapy.

Case Study in Identifying and Avoiding Drug Injury in Older Adults

• Apply age-sensitive principles for medication dosing and management to clinical scenarios.

Session 2: Optimizing Drug Therapy and Avoiding Drug Injury in Older Adults

• List nine key questions useful for identifying and managing inappropriate polypharmacy (i.e. unnecessary medication use) in older adults.​

• Discuss high risk drug-drug and drug-dietary supplement interactions commonly encountered in primary care, including best practices in identifying and managing related toxicities.

Case Study in Optimizing Drug Therapy in Older Adults ​

• Apply practical tools to screen and appropriately manage complex drug regimens among older adults with or at-risk for drug injury. ​

Session 3: Drug Therapy for Depression

• Discuss pharmacologic management options within clinical cases of adults with depression. ​

• Relate physiologic and pathophysiologic alternations of brain neurochemistry to symptoms of depression, including the genetic link and molecular basis of injury.​

• Apply clinical practice guidelines for antidepressant therapies​.

• Describe key parameters for medications used to treat mechanism, safety, tolerability, efficacy, cost, and simplicity of use. ​

Case Study in Diabetes and Depression-diagnosis and treatment ​

• Apply practical tools to screen diabetic patients for depression and appropriately manage depression in diabetic patients. ​

Session 4: Medical Management of Common Substance Use Disorders

• Explore evidence-based treatment approaches for substance use disorders.

• Discuss strategies to fully engage patients and their families in the process, including shared decision-making and building trust.

• ·Gain insights into pharmacotherapeutic treatments, including their mechanisms of action, risks, and benefits as well as relevant psychosocial and psychotherapeutic interventions.

• Explain recommendations from the American College of Cardiology/American Heart Association guidelines for treatment of patients with hypertension, hypercholesterolemia, chronic coronary disease, peripheral arterial disease, heart failure, and atrial fibrillation.

• Identify how future cardiovascular risk is estimated in primary prevention patients using the Pooled Cohort Equations and PREVENT calculator.

• List recommendations from the ACC Expert Consensus Decision Pathway for nonstatins and treatment of hypertriglyceridemia.

• List guideline recommendations supporting the use of antiplatelet therapy for primary prevention patients.

• Summarize the evidence-based CV risk reduction benefits of medications used to treat overweight and obese patients.

• Recognize the role of colchicine in the prevention of CV events.

• Select treatment plans that reduce the risk of cardiovascular disease.